An unapproved fragment with a negative development program versus approved, product-specific semaglutide medicines.
Bottom line: Semaglutide has FDA-approved products for specific indications. AOD-9604 is not an equivalent alternative: its largest reviewed trial did not show significant weight loss. [1–4]
| AOD-9604 | Semaglutide | |
|---|---|---|
| Evidence | The largest reviewed 24-week trial did not show statistically significant weight loss versus placebo. [1] | Randomized trials and FDA-reviewed product applications support named semaglutide products. [2,3] |
| Regulatory status | Not FDA-approved; no established consumer dose or preparation. [1] | Approved only as named products such as Wegovy, Wegovy HD, Ozempic and Rybelsus for labeled uses. [2,3] |
| Preparation | No validated patient reconstitution recipe. | Use the exact approved product or dispensing instructions; do not transfer directions between products. [3,4] |
summary: Semaglutide has FDA-approved products for specific indications. AOD-9604 is not an equivalent alternative: its largest reviewed trial did not show significant weight loss. [1–4]
trials: []
No. It compares evidence and status. Use the exact approved label and prescriber plan, or a registered clinical-trial protocol if you are enrolled.
Educational evidence summary. Approved products, patient-specific compounded preparations, clinical-trial products, and research-market products are not interchangeable categories.
